Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Reports Annual Financial Results for 2019 and Provides Business ReviewJanuary 25, 2021

Emmaus Life Sciences, Inc., reported today its financial results for the year ended December 31, 2019 and its restated financial results for the year ended December 31, 2018.

Michigan Revises Prior Authorization Criteria for Endari®December 10, 2020

Emmaus Life Sciences, Inc., announced today that it was notified by the Michigan Department of Health and Human Services (MDHHS) that the prior authorization criteria for Endari® was revised after being reviewed by Michigan’s Medicaid Health Plan Common Formulary Workgroup.

Emmaus Life Sciences Launches Endari® Support ProgramDecember 08, 2020

Emmaus Life Sciences, Inc., announced today the launch of the Endari® Support Program.

Endari® Granted Orphan Drug Status in SwitzerlandDecember 03, 2020

Emmaus Life Sciences, Inc., announced today that the Swiss Agency for Therapeutic Products (Swissmedic) has granted orphan drug status to Endari®.

Emmaus Life Sciences Submits Temporary License Application in Bahrain for Endari®November 10, 2020

Emmaus Life Sciences, Inc., announced today that it has submitted a temporary license application for Endari® to the National Health Regulatory Authority in the Kingdom of Bahrain.